Navigation Links
FPC Submits Updated Guidance for 2013 and Preliminary Guidance for 2014
Date:9/22/2013

GOTHENBURG, Sweden and NEW YORK, September 23, 2013 /PRNewswire/ --



Fingerprint Cards (FPC) today presents updated guidance for 2013, a preliminary forecast for 2014 and an updated market outlook for 2014 and 2015.

Due to the ongoing interest in the company following Apple's launch of Touch ID last week and ahead of imminent meetings with investors and analysts, the Board of Directors of FPC has decided to provide new and updated guidance.

  • FPC expects that sales in the third quarter of 2013 will be in the range of SEK 27-33 M.  FPC had previously provided guidance for sales in the range of SEK 20-30 M.
  • FPC continues to expect that sales in the fourth quarter of 2013 should be in the range of SEK 30-50 M.
  • Based on current market conditions, FPC currently anticipates that sales for 2014 will exceed SEK 500 M, assuming significant growth in the second half of 2014 relative to the first half of the year.
  • FPC estimates that the company will be able to report profitability as of the third quarter of 2014 with EBITDA margins rising quarter by quarter, exceeding 20% for the full year and approaching 30% for the fourth quarter of 2014.
  • FPC expects that all Tier 1 smartphone OEMs will have a capacitive fingerprint sensor in their flagship models by the end of 2014.
  • FPC estimates that the market for integrated sensors in consumer electronics will be in excess of 500 million units in 2014.
  • FPC estimates that the market for integrated sensors in consumer electronics will be in excess of 3 billion units in 2015.
  • FPC targets a 60% market share for touch sensors in smartphones in 2014-15 (excluding Apple)
  • The FPC 1020, FPC's new touch sensor which is optimized for smartphones and tablets, is scheduled for launch during the first quarter of 2014.
  • The above assessments are due to the industry's rapid advances and are subject to considerable uncertainty.

About Fingerprint Cards AB (publ)

Fingerprint Cards AB (FPC) markets, develops and produces biometric components and technologies that through the analysis and matching of an individual's unique fingerprint verify the person's identity. The technology consists of biometric sensors, processors, algorithms and modules that can be used separately or in combination with each other. The competitive advantages offered by the FPC's technology include unique image quality, extreme robustness, low power consumption and complete biometric systems. With these advantages and the ability to achieve extremely low manufacturing costs, the technology can be implemented in volume products such as smart cards and mobile phones, where extremely rigorous demands are placed on such characteristics. The company's technology can also be used in IT and Internet security, access control, etc.

Fingerprint Cards AB (publ) discloses this information pursuant to the Swedish Securities Market Act (2007:528) and the Swedish Financial Instruments Trading Act (1991:980). The information was issued for publication on September 23, 2013 at 8:00 a.m. CET.

Important information

Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any of the company's securities in any jurisdiction.

For further information, contact: Johan Carlström, CEO Fingerprint Cards AB (publ), +46(0)31-60-78-20, investrel@fingerprints.com


'/>"/>
SOURCE Fingerprint Cards AB
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
2. Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
3. Marrone Bio Innovations Submits New Bioherbicide for EPA Registration
4. Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
5. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
6. Laboratory Equipment Marketplace LabX.com Receives Fresh Look and Updated Features
7. Conflict of Interest Management Tool Updated with Administrative Dashboards
8. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
9. Scientific Research & Development in the US Industry Market Research Report from IBISWorld has Been Updated
10. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
11. NSG Precision Cells Has Updated its Fluorescence Cell Line with New Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... IPSWICH, Mass. , Feb. 17, 2017 /PRNewswire/ ... a small tumor had a mutation-conferring resistance to ... treatment. Recently, genomics research has focused on finding ... — or even from circulating tumor DNA in ... identify new oncology therapeutics. Unfortunately, however, ...
(Date:2/16/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing ... treatment for triple negative breast cancer (TNBC), announced today their ... program. The YEi Start in ... entrepreneurs grow their business in France ... selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... 2017  Champions Oncology, Inc. (NASDAQ: CSBR ... of advanced technology solutions and products to personalize the ... addition of new cohorts of PDX models to their ... expand Champions, product line in hepatocellular cancer, breast cancer, ... and non-small cell lung cancer (including EGFR mutation; ALK/ROS1 ...
Breaking Biology Technology:
(Date:1/21/2017)... Research and Markets has announced the addition ... to their offering. ... The global voice recognition biometrics market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
Breaking Biology News(10 mins):